Anna Antipov

Dr. Anna Antipov

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2023 in Immunology
Verified
Journal Article
Closed access
YHYoshikazu Honda-Okubo
Yoshikazu Honda-Okubo
AAAnna Antipov
Anna Antipov
GAGreiciely Andre
Greiciely Andre
SBSaghar Barati
Saghar Barati
HKHamidreza Kafi
Hamidreza Kafi
NPNikolai Petrovsky
Nikolai Petrovsky

12 February 2024 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Closed access
DMDavid McLelland
David McLelland
MLMichael Lynch
Michael Lynch
LVLarry Vogelnest
Larry Vogelnest
PEPaul Eden
Paul Eden
AWAlisa Wallace
Alisa Wallace
NPNikolai Petrovsky
Nikolai Petrovsky

1 April 2020 in Brain Research
Verified
Journal Article
Closed access
AAAnna Antipov
Anna Antipov
MBMariana Brizuela
Mariana Brizuela
WBWilliam W. Blessing
William W. Blessing
YOYouichirou Ootsuka
Youichirou Ootsuka

21 June 2025 in Burns
Verified
Journal Article
Open access
AGAnteneh Amsalu Geremew
Anteneh Amsalu Geremew
AAAnton Alvaro
Anton Alvaro
SHSteven Huang
Steven Huang
AMAndrew May
Andrew May
AAAnna Antipov
Anna Antipov
Zlatko KopeckiZlatko Kopecki
Zlatko Kopecki
To define the microbiome, antimicrobial resistance profiles and associated risk factors among paediatric patients with infected burns. A retrospective cohort study was conducted among paediatric patients with infected burns admitted to a tertiary burns service between January 2011 to December 2023. Basic demographic data and burn-related clinical information were extracted from the Burns Unit database and linked with microbiological data. Among a total of 3679 paediatric burn patients admitted, 183 (5 % of overall admitted) were identified as clinically having infected burns. Of the 173 (4.7 % of overall admitted) patients with documented cultures, 152 (87.9 % of suspected clinical infections) had culture-positive burn wound infections (BWIs) and 15 (8.7 % of overall admitted) had developed blood stream infections. The most common microorganisms identified in BWI were Gram-positive bacteria (245 isolates, 63.1 %), with Staphylococcus aureus being the most prevalent (32 %) followed by Streptococcus species (11.9 %). Gram-negative bacteria were identified in 32.5 % of cases, with Pseudomonas aeruginosa being the most common organism (5.7 %). Nineteen (5 %) methicillin-resistant Staphylococcus aureus isolates were detected from 17 (9.8 %) paediatric patients with burns. The highest resistance was reported against ampicillin (100 %) followed by penicillin (91.7 %), and amoxicillin (88.6 %) against S. aureus isolates. P. aeruginosa isolates showed resistance in 58.8 % of cases to ceftazidime, followed by 47 % to piperacillin-tazobactam, and 2 isolates were resistant to imipenem, a carbapenem antibiotic considered a last-resort option. Multivariate logistic regression analysis revealed that burns to the head and neck regions (AOR = 5.2, 95 %CI: 2.20-12.31; p < 0.001), admission to the paediatric intensive care unit (PICU) (AOR = 8.2, 95 %CI: 1.03-64.86; p = 0.047) and previous medical history (AOR = 2.4, 95 %CI: 1.07-5.55; p = 0.033) were independent risk factors associated with antimicrobial-resistant (AMR) burn infections CONCLUSIONS: AMR in paediatric patients with infected burns is common and therefore early culture confirmation could improve treatment outcomes especially for patients with high risk factors.

24 April 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
PSPedro Luis Sanchez
Pedro Luis Sanchez
GAGreiciely Andre
Greiciely Andre
AAAnna Antipov
Anna Antipov
NPNikolai Petrovsky
Nikolai Petrovsky
TRTed Ross
Ted Ross
Adjuvants enhance immune responses stimulated by vaccines. To date, many seasonal influenza vaccines are not formulated with an adjuvant. In the present study, the adjuvant Advax-SM™ was combined with next generation, broadly reactive influenza hemagglutinin (HA) vaccines that were designed using a computationally optimized broadly reactive antigen (COBRA) methodology. Advax-SM™ is a novel adjuvant comprising inulin polysaccharide and CpG55.2, a TLR9 agonist. COBRA HA vaccines were combined with Advax-SM™ or a comparator squalene emulsion (SE) adjuvant and administered to mice intramuscularly. Mice vaccinated with Advax-SM™ adjuvanted COBRA HA vaccines had increased serum levels of anti-influenza IgG and IgA, high hemagglutination inhibition activity against a panel of H1N1 and H3N2 influenza viruses, and increased anti-influenza antibody secreting cells isolated from spleens. COBRA HA plus Advax-SM™ immunized mice were protected against both morbidity and mortality following viral challenge and, at postmortem, had no detectable lung viral titers or lung inflammation. Overall, the Advax-SM™-adjuvanted COBRA HA formulation provided effective protection against drifted H1N1 and H3N2 influenza viruses.

24 August 2026 in Microbiologyopen
Verified
Journal Article
Open access
AAAnteneh Amsalu
Anteneh Amsalu
AAAnton Alvaro
Anton Alvaro
LQLinda Quinn
Linda Quinn
AAAnna Antipov
Anna Antipov
SSSylvia Sapula
Sylvia Sapula
ZKZlatko Kopecki
Zlatko Kopecki
Burn injuries predispose paediatric patients to infection, and rising antimicrobial resistance (AMR) is reducing the effectiveness of conventional antibiotics. This underscores the need for novel antimicrobial dressings. This study characterised the microbiome and AMR profiles of paediatric burn wounds and assessed the antimicrobial efficacy of a silver nanoparticle (AgNP) hydrogel against clinical isolates. Twenty paediatric burn patients were recruited over a year, and 21 burn wounds were sampled. Three swabs were collected from each wound: one for full‐length 16S rRNA sequencing, one for species identification, and one for routine microbiology. Eleven wounds (from 10 patients) were clinically infected, and 10 were uninfected. Bacterial identification used standard culture methods and MALDI‐TOF. Antimicrobial susceptibility was determined using disk diffusion assays, and AgNP hydrogel efficacy was evaluated via agar‐well diffusion assay. Most patients were male (65%), under 5 years of age (55%), and had sustained scald burns (60%). Maximal burn depth significantly increased the likelihood of infection ( p = 0.021) and subsequent systemic antibiotic use ( p = 0.02). Clinically infected wounds exhibited significantly reduced alpha diversity, while beta diversity showed no distinct clustering by infection status. Staphylococcus aureus was enriched in infected wounds, whereas S. epidermidis predominated in uninfected wounds. Culture analyses revealed high penicillin resistance among Staphylococci and cefoxitin resistance in three coagulase‐negative strains. Five isolates demonstrated multidrug resistance. The AgNP hydrogel showed broad‐spectrum activity against all isolates, including multidrug‐resistant organisms. The AgNP hydrogel demonstrates antimicrobial activity against resistant burn wound pathogens. Large studies are required to support its clinical translation.